About this Clinical Study
Netherton syndrome (NS) is a rare hereditary genetic skin disease characterized by scaling skin, hair anomalies, increased susceptibility to atopic eczema (a skin condition that can result in dry, red and flaky skin), elevated IgE levels, and other related symptoms. Currently, there is no FDA approved treatment(s) or cures for NS. Healthcare providers frequently use treatments such as topical corticosteroids, topical calcineurin inhibitors, topical retinoids, narrowband ultraviolet B phototherapy, psoralen and ultraviolet irradiation, and oral acitretin, although their success varies. Quoin Pharmaceuticals, Ltd. is developing a topical medication containing a new investigational active ingredient, combined with a proprietary polymer delivery system, for the treatment of NS. With that being said, we are pleased to inform you that Quoin is now initiating a new Phase 2 study under the guidance of FDA.
Study #1
Our Comparator Trial
(Active vs Vehicle)
Participants must be male or female (not pregnant or breastfeeding), 14 years or older, and in good general health with a clinical diagnosis of NS (genetic testing may also be required). Participants must have NS lesions on arms or lower legs and be off all other medications in these areas. Qualified patients will receive up to 12 weeks of treatment, with approximately two-thirds of the enrolled patients receiving the active medication.
Study #2
Our Open Label Trial
Participants must be male or female (not pregnant or breastfeeding), 14 years or older, and in good general health with a clinical diagnosis of NS (genetic testing may also be required). Patients must have NS lesions on arms or lower legs. Participants must currently be taking systemic therapy and will be required to continue their standard of care, including systemic therapy, for the duration of the study but must be willing to wash out of their topical therapy, if any, in the area where the investigational treatment will be applied. All qualified patients will receive up to 12 weeks of treatment with the active medication.
Qualified participants will receive study-related examinations by a physician, genetic testing to confirm Netherton syndrome, all study visits, and study drugs. Compensation for time and participation will also be provided. Additionally, if significant travel is necessary to reach a clinical research site, travel expenses such as airfare, meals, and lodging may be reimbursed for the patient and one accompanying parent (in the case of a child).
​
If you are interested in participating in one of these exciting studies, please take a brief survey to see if you qualify.
Or Contact Us:​
Call:
858-571-1800 ext 151
Email: Cooke@therapeuticsinc.com​
​
Thank you for your interest in this potential therapy for NS.
